Your browser doesn't support javascript.
loading
Tailored immunotherapy approach with nivolumab with or without nivolumab plus ipilimumab as immunotherapeutic boost in patients with metastatic renal cell carcinoma (TITAN-RCC): a multicentre, single-arm, phase 2 trial.
Grimm, Marc-Oliver; Esteban, Emilio; Barthélémy, Philippe; Schmidinger, Manuela; Busch, Jonas; Valderrama, Begoña P; Charnley, Natalie; Schmitz, Marc; Schumacher, Ulrike; Leucht, Katharina; Foller, Susan; Baretton, Gustavo; Duran, Ignacio; de Velasco, Guillermo; Priou, Frank; Maroto, Pablo; Albiges, Laurence.
Affiliation
  • Grimm MO; Department of Urology, Jena University Hospital, Friedrich-Schiller University, Jena, Germany. Electronic address: marc-oliver.grimm@med.uni-jena.de.
  • Esteban E; Department of Medical Oncology, Hospital Universitario Central de Asturias, Oviedo, Spain.
  • Barthélémy P; Department of Medical Oncology, Institut de Cancérologie Strasbourg Europe, Strasbourg, France.
  • Schmidinger M; Department of Urology, Medical University of Vienna, Vienna, Austria.
  • Busch J; Department of Urology, University Hospital Charité Berlin, Berlin, Germany.
  • Valderrama BP; Department of Medical Oncology, Hospital Universitario Virgen del Rocío, Seville, Spain.
  • Charnley N; Department of Oncology, Royal Preston Hospital, Preston, UK.
  • Schmitz M; Institute of Immunology, Faculty of Medicine Carl Gustav Carus, Technical University of Dresden, Dresden, Germany; National Center for Tumor Diseases, Dresden, Germany; German Cancer Consortium, Dresden, Germany; German Cancer Research Center, Heidelberg, Germany.
  • Schumacher U; Center for Clinical Studies, Jena University Hospital, Friedrich-Schiller University, Jena, Germany.
  • Leucht K; Department of Urology, Jena University Hospital, Friedrich-Schiller University, Jena, Germany.
  • Foller S; Department of Urology, Jena University Hospital, Friedrich-Schiller University, Jena, Germany.
  • Baretton G; Institute of Pathology, Faculty of Medicine Carl Gustav Carus, Technical University of Dresden, Dresden, Germany.
  • Duran I; Hospital Universitario Marqués de Valdecilla, Instituto de Investigación Marqués de Valdecilla, Santander, Spain.
  • de Velasco G; Department of Oncology, Hospital 12 de Octubre, Madrid, Spain.
  • Priou F; Centre Hospitalier Départemental Vendee, Hopital Les Oudairies, La Roche Sur Yon, France.
  • Maroto P; Department of Medical Oncology, Hospital de la Santa Creu I Sant Pau, Barcelona, Spain.
  • Albiges L; Department of Cancer Medicine, Gustave Roussy, University of Paris Saclay, Villejuif, France.
Lancet Oncol ; 24(11): 1252-1265, 2023 Nov.
Article in En | MEDLINE | ID: mdl-37844597
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Renal Cell / Brain Ischemia / Stroke / Kidney Neoplasms Limits: Adolescent / Adult / Female / Humans / Male Language: En Journal: Lancet Oncol Journal subject: NEOPLASIAS Year: 2023 Document type: Article
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Renal Cell / Brain Ischemia / Stroke / Kidney Neoplasms Limits: Adolescent / Adult / Female / Humans / Male Language: En Journal: Lancet Oncol Journal subject: NEOPLASIAS Year: 2023 Document type: Article